JP6513095B2 - ヘテロ原子含有デオキシウリジントリホスファターゼ阻害剤 - Google Patents
ヘテロ原子含有デオキシウリジントリホスファターゼ阻害剤 Download PDFInfo
- Publication number
- JP6513095B2 JP6513095B2 JP2016544133A JP2016544133A JP6513095B2 JP 6513095 B2 JP6513095 B2 JP 6513095B2 JP 2016544133 A JP2016544133 A JP 2016544133A JP 2016544133 A JP2016544133 A JP 2016544133A JP 6513095 B2 JP6513095 B2 JP 6513095B2
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- dutpase
- alkyl
- group
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461923534P | 2014-01-03 | 2014-01-03 | |
| US61/923,534 | 2014-01-03 | ||
| PCT/US2015/010059 WO2015103489A1 (en) | 2014-01-03 | 2015-01-02 | Heteroatom containing deoxyuridine triphosphatase inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017502967A JP2017502967A (ja) | 2017-01-26 |
| JP2017502967A5 JP2017502967A5 (enExample) | 2018-02-08 |
| JP6513095B2 true JP6513095B2 (ja) | 2019-05-15 |
Family
ID=53494059
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016544133A Active JP6513095B2 (ja) | 2014-01-03 | 2015-01-02 | ヘテロ原子含有デオキシウリジントリホスファターゼ阻害剤 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US9790214B2 (enExample) |
| EP (1) | EP3089964B1 (enExample) |
| JP (1) | JP6513095B2 (enExample) |
| CN (1) | CN106061952B (enExample) |
| CA (1) | CA2935717C (enExample) |
| IL (1) | IL246545B (enExample) |
| WO (1) | WO2015103489A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6450323B2 (ja) | 2013-01-07 | 2019-01-09 | ユニバーシティ オブ サザン カリフォルニア | デオキシウリジントリホスファターゼ阻害剤 |
| CA2935717C (en) | 2014-01-03 | 2022-06-21 | University Of Southern California | Uracil isostere and pharmaceutical compositions thereof useful as deoxyuridine triphosphatase inhibitors |
| WO2017006283A1 (en) | 2015-07-08 | 2017-01-12 | Cv6 Therapeutics (Ni) Limited | Deoxyuridine triphosphatase inhibitors containing cyclopropano linkage |
| SI3319939T1 (sl) | 2015-07-08 | 2025-04-30 | Cv6 Therapeutics (Ni) Limited | Zaviralci deoksiuridin trifosfataze, ki vsebujejo hidantoin |
| WO2017006270A1 (en) | 2015-07-08 | 2017-01-12 | University Of Southern California | Deoxyuridine triphosphatase inhibitors |
| WO2017006271A1 (en) | 2015-07-08 | 2017-01-12 | University Of Southern California | Deoxyuridine triphosphatase inhibitors containing amino sulfonyl linkage |
| WO2018098208A1 (en) | 2016-11-23 | 2018-05-31 | Cv6 Therapeutics (Ni) Limited | Nitrogen ring linked deoxyuridine triphosphatase inhibitors |
| US11014924B2 (en) | 2016-11-23 | 2021-05-25 | Cv6 Therapeutics (Ni) Limited | Hydantoin containing deoxyuridine triphosphatase inhibitors |
| US10858344B2 (en) | 2016-11-23 | 2020-12-08 | Cv6 Therapeutics (Ni) Limited | Hydantoin containing deoxyuridine triphosphatase inhibitors |
| US11168059B2 (en) | 2016-11-23 | 2021-11-09 | Cv6 Therapeutics (Ni) Limited | Amino sulfonyl compounds |
| US11174271B2 (en) | 2016-11-23 | 2021-11-16 | Cv6 Therapeutics (Ni) Limited | 6-membered uracil isosteres |
| US11247984B2 (en) | 2017-01-05 | 2022-02-15 | Cv6 Therapeutics (Ni) Limited | Uracil containing compounds |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE787766A (fr) | 1971-08-21 | 1973-02-19 | Merck Patent Gmbh | Imides d'acide glutarique et leur procede de preparation |
| US4304715A (en) | 1979-06-08 | 1981-12-08 | Derek Hudson | Enkephalin analogues |
| JPS5839672A (ja) | 1981-09-03 | 1983-03-08 | Chugai Pharmaceut Co Ltd | ウラシル誘導体 |
| JPH0674251B2 (ja) * | 1986-02-07 | 1994-09-21 | 全薬工業株式▲会▼社 | ビス−ジオキソピペラジン誘導体 |
| JPS63101361A (ja) | 1986-09-08 | 1988-05-06 | ブリティッシュ・テクノロジー・グループ・リミテッド | ジオキソピペリジン誘導体を含有する不安解消組成物 |
| FR2644786B1 (fr) * | 1989-03-21 | 1993-12-31 | Adir Cie | Nouveaux derives fluoro-4 benzoiques, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent |
| US5463063A (en) | 1993-07-02 | 1995-10-31 | Celgene Corporation | Ring closure of N-phthaloylglutamines |
| US5599796A (en) * | 1993-12-02 | 1997-02-04 | Emory University | Treatment of urogenital cancer with boron neutron capture therapy |
| US5962246A (en) | 1996-03-29 | 1999-10-05 | The University Of Medicine And Dentistry Of New Jersey | dUTPase, its isoforms, and diagnostic and other uses |
| JPH09286786A (ja) | 1996-04-18 | 1997-11-04 | Nippon Paper Ind Co Ltd | ピリミジン誘導体及びその抗腫瘍剤としての用途 |
| ES2302363T3 (es) | 1997-12-18 | 2008-07-01 | Boehringer Ingelheim Pharmaceuticals Inc. | Piridonas como inhibidores del dominia sh2 del grupo src. |
| WO2000059874A1 (en) | 1999-04-02 | 2000-10-12 | Du Pont Pharmaceuticals Company | NOVEL AMIDE DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES, TNF-α, AND AGGRECANASE |
| DE10002509A1 (de) | 2000-01-21 | 2001-07-26 | Gruenenthal Gmbh | Substituierte Glutarimide |
| JP2002284686A (ja) | 2001-03-28 | 2002-10-03 | Sankyo Co Ltd | スルホンアミド化合物を含有する医薬組成物 |
| CA2444148A1 (en) | 2001-04-11 | 2002-10-24 | Queen's University At Kingston | Pyrimidine compounds as anti-ictogenic and/or anti-epileptogenic agents |
| US6822097B1 (en) | 2002-02-07 | 2004-11-23 | Amgen, Inc. | Compounds and methods of uses |
| GB0400290D0 (en) | 2004-01-08 | 2004-02-11 | Medivir Ab | dUTPase inhibitors |
| CA2595711A1 (en) | 2005-01-25 | 2006-08-03 | Celgene Corporation | Methods and compositions using 4-amino-2-(3-methyl-2,6-dioxopiperidin-3-yl)-isoindole-1-3-dione |
| WO2006135763A2 (en) | 2005-06-09 | 2006-12-21 | The Johns Hopkins University | Inhibitors of dna repair enzymes and methods of use thereof |
| SG174016A1 (en) | 2006-07-24 | 2011-09-29 | Korea Res Inst Chem Tech | Hiv reverse transcriptase inhibitors |
| EP1939186A1 (en) | 2006-12-22 | 2008-07-02 | Sulfidris S.r.l. | 5-Fluorouracil derivatives and their use for the treatment of cancer |
| EA017919B1 (ru) | 2007-12-10 | 2013-04-30 | Новартис Аг | Производные пиразин-2-карбоксамида для лечения заболеваний, которые поддаются лечению путем блокирования эпителиальных натриевых каналов |
| EP2295414B1 (en) | 2008-06-03 | 2012-09-26 | Taiho Pharmaceutical Co., Ltd. | Uracil compound having inhibitory activity on human deoxyuridine triphosphatase or salt thereof |
| WO2010025308A2 (en) | 2008-08-27 | 2010-03-04 | Universtiy Of Southern California | Inhibitors of dutpase |
| JP2011231015A (ja) | 2008-08-29 | 2011-11-17 | Taiho Yakuhin Kogyo Kk | 含窒素複素環を有する新規ウラシル化合物又はその塩 |
| JP2012518029A (ja) | 2009-02-19 | 2012-08-09 | ノヴォ・ノルディスク・アー／エス | 第ｖｉｉｉ因子の修飾 |
| EP2508185B1 (en) | 2009-11-30 | 2020-03-04 | Taiho Pharmaceutical Co., Ltd. | Anti-tumor effect potentiator |
| JP2013032293A (ja) | 2009-11-30 | 2013-02-14 | Taiho Yakuhin Kogyo Kk | ヒトｄＵＴＰａｓｅ阻害活性を有する５−フルオロウラシル化合物又はその塩 |
| JP2013047189A (ja) | 2009-12-25 | 2013-03-07 | Kyorin Pharmaceutical Co Ltd | 新規パラバン酸誘導体及びそれらを有効成分とする医薬 |
| GB201020032D0 (en) | 2010-11-25 | 2011-01-12 | Sigmoid Pharma Ltd | Composition |
| PL2508158T3 (pl) | 2011-04-04 | 2014-11-28 | Arjo Hospital Equipment Ab | Urządzenie wciągnikowe |
| JP6450323B2 (ja) * | 2013-01-07 | 2019-01-09 | ユニバーシティ オブ サザン カリフォルニア | デオキシウリジントリホスファターゼ阻害剤 |
| CA2935717C (en) | 2014-01-03 | 2022-06-21 | University Of Southern California | Uracil isostere and pharmaceutical compositions thereof useful as deoxyuridine triphosphatase inhibitors |
| JP6364546B2 (ja) | 2015-04-30 | 2018-07-25 | 大鵬薬品工業株式会社 | 抗腫瘍剤の副作用軽減剤 |
| MX382561B (es) | 2015-05-01 | 2025-03-11 | Taiho Pharmaceutical Co Ltd | Cristal novedoso de compuesto uracilo |
| WO2017006271A1 (en) | 2015-07-08 | 2017-01-12 | University Of Southern California | Deoxyuridine triphosphatase inhibitors containing amino sulfonyl linkage |
| WO2017006283A1 (en) | 2015-07-08 | 2017-01-12 | Cv6 Therapeutics (Ni) Limited | Deoxyuridine triphosphatase inhibitors containing cyclopropano linkage |
| WO2017006270A1 (en) | 2015-07-08 | 2017-01-12 | University Of Southern California | Deoxyuridine triphosphatase inhibitors |
| SI3319939T1 (sl) | 2015-07-08 | 2025-04-30 | Cv6 Therapeutics (Ni) Limited | Zaviralci deoksiuridin trifosfataze, ki vsebujejo hidantoin |
-
2015
- 2015-01-02 CA CA2935717A patent/CA2935717C/en active Active
- 2015-01-02 US US15/109,616 patent/US9790214B2/en active Active
- 2015-01-02 JP JP2016544133A patent/JP6513095B2/ja active Active
- 2015-01-02 EP EP15733304.8A patent/EP3089964B1/en active Active
- 2015-01-02 WO PCT/US2015/010059 patent/WO2015103489A1/en not_active Ceased
- 2015-01-02 CN CN201580012064.6A patent/CN106061952B/zh active Active
-
2016
- 2016-06-30 IL IL246545A patent/IL246545B/en active IP Right Grant
-
2017
- 2017-09-28 US US15/719,165 patent/US10457673B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3089964B1 (en) | 2021-02-24 |
| CA2935717A1 (en) | 2015-07-09 |
| IL246545B (en) | 2020-05-31 |
| US20180086746A1 (en) | 2018-03-29 |
| US9790214B2 (en) | 2017-10-17 |
| EP3089964A4 (en) | 2018-01-17 |
| CA2935717C (en) | 2022-06-21 |
| US10457673B2 (en) | 2019-10-29 |
| CN106061952A (zh) | 2016-10-26 |
| CN106061952B (zh) | 2022-01-28 |
| US20160326149A1 (en) | 2016-11-10 |
| WO2015103489A1 (en) | 2015-07-09 |
| EP3089964A1 (en) | 2016-11-09 |
| IL246545A0 (en) | 2016-08-31 |
| JP2017502967A (ja) | 2017-01-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6660993B2 (ja) | デオキシウリジントリホスファターゼ阻害剤 | |
| US11124485B2 (en) | Deoxyuridine triphosphatase inhibitors containing cyclopropano linkage | |
| US11479531B2 (en) | Deoxyuridine triphosphatase inhibitors | |
| US11198677B2 (en) | Deoxyuridine triphosphatase inhibitors containing amino sulfonyl linkage | |
| CN106061952B (zh) | 含有杂原子的脱氧尿苷三磷酸酶抑制剂 | |
| US11168059B2 (en) | Amino sulfonyl compounds | |
| WO2018128720A1 (en) | Uracil containing compounds | |
| JP7445609B2 (ja) | Ｅｐａｃ阻害剤としてのチエノ［２，３－ｂ］ピリジン誘導体及びその医薬用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20171220 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20171220 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180911 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20180913 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20181210 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20190312 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20190409 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6513095 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |